Back to results
US 11,590,170 B2Granted
Chimeric antigen receptor
AssigneeAutolus Limited
InventorsMartin Pulé, Evangelia Kokalaki, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Biao Ma, Mathieu Ferrari
Life of this patent
Estimating the term…
Abstract
The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.
Claims6
A cytolytic T cell expressing an anti-CD22 chimeric antigen receptor (CAR) and an anti-CD19 CAR, wherein:
- a) the anti-CD22 CAR comprises a VH domain comprising the sequence of SEQ ID NO:
- 65 and a VL domain comprising the sequence of SEQ ID NO:
- 66, human CD8 stalk and transmembrane domain, human 4-1BB co-stimulatory domain and human CD3ζ endodomain, and
- b) the anti-CD19 CAR comprises a VH domain comprising the sequence of SEQ ID NO:
- 75 and a VL domain comprising the sequence of SEQ ID NO:
- 76, human CD8 stalk and transmembrane domain, human 4-1BB co-stimulatory domain and human CD3ζ endodomain.
3 more elements
A kit comprising:
- a) a vector encoding an anti-CD22 CAR, wherein the anti-CD22 CAR comprises a VH domain comprising the sequence of SEQ ID NO:
- 65 and a VL domain comprising the sequence of SEQ ID NO:
- 66, human CD8 stalk and transmembrane domain, human 4-1BB co-stimulatory domain and human CD3ζ endodomain, and
- b) a vector encoding an anti-CD19 CAR, wherein the anti-CD19 CAR comprises a VH domain comprising the sequence of SEQ ID NO:
- 75 and a VL domain comprising the sequence of SEQ ID NO:
- 76, human CD8 stalk and transmembrane domain, human 4-1BB co-stimulatory domain and human CD3ζ endodomain.
3 more elements
Dependencies are inferred from the claim text.